Literature DB >> 10716143

A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients.

G Montalescot, J P Collet, R Choussat, A Ankri, D Thomas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716143     DOI: 10.1016/s0167-5273(99)00202-8

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  5 in total

1.  Increased serum levels of interleukin-6 and von Willenbrand Factor in early phase of acute coronary syndrome in a young and multiethnic Malaysian population.

Authors:  Wen Ni Tiong; Alan Yean Yip Fong; Edmund Ui Hang Sim; Hiang Chuan Chan; Tiong Kiam Ong; Boon Cheng Chang; Kui Hian Sim
Journal:  Heart Asia       Date:  2012-10-16

2.  Circulating Endothelial Cells and Endothelial Function Predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Magdy Abdel Hamid; Sameh W G Bakhoum; Yasser Sharaf; Dina Sabry; Ahmed T El-Gengehe; Ahmed Abdel-Latif
Journal:  J Interv Cardiol       Date:  2016-02       Impact factor: 2.279

Review 3.  Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.

Authors:  Marc Cohen
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital.

Authors:  Akram Ahmad; Isha Patel; Himani Asani; M Jagadeesan; S Parimalakrishnan; S Selvamuthukumaran
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

5.  Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events: a systematic review and meta-analysis.

Authors:  Mengge Fan; Xia Wang; Xun Peng; Shuo Feng; Junyu Zhao; Lin Liao; Yong Zhang; Yinglong Hou; Ju Liu
Journal:  BMC Cardiovasc Disord       Date:  2020-02-10       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.